A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Summary

The goal of this clinical trial is to define a safe and effective dose of DM919 for participants with solid tumors The main questions it aims to answer are: What is the safe and effective dose of DM919 when used alone or in combination with pembrolizumab? What cancers can be treated effectively with DM919 alone or in combination with pembrolizumab?? Participants will be asked to attend clinic and be given a intravenous infusion of DM919 or DM-919 in combination with pembrolizumab. They will have blood tests and other assessments to measure whether DM-919 will have the effect on tumors.

Timeline

Start

2024-04-09

Primary completion

2026-03-01

Completion

2026-03-01

Drugs

Indications